Brands
- Brands
- Pipeline
Our Brands
Within our Therapeutics business unit, our brands reflect our mission to deliver targeted, clinically meaningful solutions that address urgent and evolving patient needs. This portfolio is designed to provide healthcare providers with reliable, high-quality treatment options that support better patient outcomes across a range of therapeutic areas.
By aligning our brands under Therapeutics, we bring a unified approach to development, commercialization, and lifecycle management—ensuring each product contributes to advancing care and addressing unmet needs across the healthcare landscape.
Antibiotics
Immunology & Inflammation
XTMAB-16
More About XTMAB-16Our Pipeline
- All Products
- Anti-Infective
- Immunology & Inflammation
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Submission
- Approved
Brands
| Drug Name | Therapeutic Area | Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submission | Approved |
|---|---|---|---|---|---|---|---|---|---|
| XENLETA® (lefamulin) | Anti-Infective | Small Molecule | |||||||
| Contepo™ (fosfomycin) for injection | Anti-Infective | Small Molecule | |||||||
| XTMAB-16 | Immunology & Inflammation | Biologic | |||||||
No products match the selected filters.
You might also be interested
The brands mentioned here are the trademarks of their respective owners.
